Hanieh Rouzbahani

Hanieh Rouzbahani

Auto-generated profile, based on publicly available information

Hanieh Rouzbahani

School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MSMaryam Soheilipour
Maryam Soheilipour
ANAli Noursina
Ali Noursina
MNMohadese Nekookhoo
Mohadese Nekookhoo
EMElena Malekpour
Elena Malekpour
SMSeyed Arsham Mirzaei
Seyed Arsham Mirzaei
FSFarzad Safari
Farzad Safari
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Emerging evidence highlights the gut microbiota, particularly Akkermansia muciniphila, as a key modulator in CRC pathogenesis. While often regarded as a beneficial commensal, its role in CRC appears complex and potentially dualistic. This systematic review aims to comprehensively analyze the context-dependent role of A. muciniphila in CRC, evaluating its potential as a pathobiont. We systematically reviewed human, animal, in vitro, and ex vivo studies on associations between A. muciniphila and CRC risk or outcomes. Database searches identified 34 eligible studies. Study quality was assessed using the GRADE criteria. From 244 initial records, 34 studies met the inclusion criteria. Findings reveal a stark dichotomy: non-viable forms of A. muciniphila—including pasteurized bacteria, outer membrane vesicles (OMVs), and purified proteins (e.g., Amuc_1100, Amuc_2172, Amuc_1434*)—consistently demonstrate anti-tumorigenic effects. These components enhance anti-tumor immunity by activating CD8 + T cells, promoting M1-like macrophage polarization via TLR2/NLRP3 signaling, and sensitizing tumors to chemotherapy and anti-PD-1 immunotherapy. Conversely, administration of live A. muciniphila can exert pro-tumorigenic effects, particularly in inflammatory contexts (e.g., colitis-associated CRC) or post-antibiotic settings, likely due to excessive mucin degradation and gut barrier disruption. Host factors such as obesity, sex, genetics, and microbial interactions further modulate its impact. A. muciniphila functions as a pathobiont in CRC, with its role critically dependent on its biological state and host context. Therapeutic strategies should shift from live probiotics to targeted postbiotic applications of its beneficial components to maximize efficacy and safety.

27 December 2025 in Probiotics and Antimicrobial Proteins
Verified
Journal Article
Closed access
PDF file
FSFarzad Safari
Farzad Safari
FGFaraz Golafshan
Faraz Golafshan
EMElena Malekpour
Elena Malekpour
SMSeyed Arsham Mirzaei
Seyed Arsham Mirzaei
HRHanieh Rouzbahani
Hanieh Rouzbahani
ANAli Noursina
Ali Noursina

30 September 2026 in Bratislava Medical Journal
Verified
Journal Article
Closed access
PDF file
Hamid NasriHamid Nasri
Hamid Nasri
MCMohammad Reza Chitsazi
Mohammad Reza Chitsazi
FAFatemeh Abbasi
Fatemeh Abbasi
AAAmir Hossein Ashouri
Amir Hossein Ashouri
HRHanieh Rouzbahani
Hanieh Rouzbahani
FSFarzad Safari
Farzad Safari

15 October 2026 in Advances in Redox Research
Verified
Journal Article
Open access
FAFatemeh Abbasi
Fatemeh Abbasi
MCMohammad Reza Chitsazi
Mohammad Reza Chitsazi
MSMohammad Hossein Shafieyoun
Mohammad Hossein Shafieyoun
SMSeyed Arash Mirzaei
Seyed Arash Mirzaei
HRHanieh Rouzbahani
Hanieh Rouzbahani
FSFarzad Safari
Farzad Safari

20 June 2026 in Health Science Reports
Verified
Journal Article
Open access
MMMahtab Mashayekhi
Mahtab Mashayekhi
SSSahar Saeidi
Sahar Saeidi
GKGhazaleh Kheiri
Ghazaleh Kheiri
FSFateme Salemi
Fateme Salemi
MMMarjan Masoud
Marjan Masoud
MBMaryam Barkhordar
Maryam Barkhordar
Background and Aims: Haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) provides curative therapy for patients lacking HLA‐matched donors, yet optimal donor characteristics remain uncertain. This study assessed the effect of donor relationship, age, sex, and ABO compatibility on outcomes of haplo‐HSCT for acute leukemia under a uniform ATG/post‐transplant cyclophosphamide (PTCy)‐based protocol. Methods: In this retrospective single‐center cohort, 159 adults with acute myeloid or lymphoblastic leukemia received peripheral blood haplo‐HSCT following myeloablative busulfan/cyclophosphamide plus ATG and PTCy (2015–2022). Overall survival (OS), disease‐free survival (DFS), GVHD‐free/relapse‐free survival (GRFS), and relapse incidence were analyzed using Kaplan–Meier and Fine–Gray methods; predictors were evaluated by multivariable Cox regression. Results: Of 159 patients, 96/159 (60.4%) had AML and 63/159 (39.6%) had ALL. Donors were siblings in 90/159 (56.6%), parents in 48/159 (30.2%), and offspring in 21/159 (13.2%). Median recipient age was 27 years (range, 15–59), and median donor age was 31 years (range, 2–65). At 36 months, unadjusted outcomes varied across donor groups. In AML, OS was 52.7% (95% CI, 38.8–64.9) with sibling donors, 52.3% (95% CI, 29.4–71.0) with parent donors, and 32.1% (95% CI, 9.5–57.9) with offspring donors. In ALL, offspring donors were associated with numerically lower survival and higher relapse. In multivariable analysis, ALL (HR, 1.99; 95% CI, 1.25–3.17; p = 0.004), advanced remission status (HR, 1.79; 95% CI, 1.16–2.77; p = 0.01), and older recipient age (HR, 1.03 per year; 95% CI, 1.01–1.05; p < 0.001) were independently associated with worse OS. Donor's age, sex, relationship, and ABO compatibility were not independently associated with major outcomes. Conclusions: In this single‐center cohort of adults undergoing haploidentical HSCT with a uniform ATG/PTCy‐based platform, donor relationship was associated with descriptive differences in unadjusted outcomes, but it was not an independent predictor in multivariable models. The inferior outcomes observed with offspring donors appeared to be influenced in part by older recipient age. Trial Registration: Not applicable (retrospective study).